U.S. Cannabis Market Size, Share & Trends Report

U.S. Cannabis Market Size, Share & Trends Analysis Report By Source (Hemp, Marijuana), By Derivatives (CBD, THC), By End-use (Medical Use, Recreational Use), And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-2-68038-978-4
  • Number of Report Pages: 150
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2022
  • Forecast Period: 2024 - 2030 
  • Industry: Healthcare

Table of Contents

Chapter 1. Methodology and Scope
                   1.1. Market Segmentation & Scope
                   1.2. Segment Definitions
                       1.2.1. Source
                       1.2.2. Derivatives
                       1.2.3. End-use
                   1.3. Estimates and Forecast Timeline
                   1.4. Research Methodology
                   1.5. Information Procurement
                       1.5.1. Purchased Database
                       1.5.2. GVR’s Internal Database
                       1.5.3. Secondary Sources
                       1.5.4. Primary Research
                   1.6. Information Analysis
                       1.6.1. Data Analysis Models
                   1.7. Market Formulation & Data Visualization
                   1.8. Model Details
                       1.8.1. Commodity Flow Analysis
                   1.9. List of Secondary Sources
                   1.10. Objectives
Chapter 2. Executive Summary
                   2.1. Market Snapshot
                   2.2. Segment Snapshot
                       2.2.1. Source outlook
                       2.2.2. Derivatives outlook
                       2.2.3. End-use outlook
                   2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Cannabis Market Variables, Trends, & Scope
                   3.1. Market Lineage Outlook
                   3.2. Market Dynamics
                       3.2.1. Market Driver Analysis
                           3.2.1.1. Growing adoption of medical marijuana for treatment of chronic diseases
                           3.2.1.2. Impending legalization of marijuana for recreational/adult use
                           3.2.1.3. Rising number of research studies on cannabis for various ailments
                           3.2.1.4. Growing legalization and awareness of cannabis in various states in the U.S.
                       3.2.2. Market Restraint Analysis
                           3.2.2.1. High cost of cannabis and CBD-based products
                           3.2.2.2. lack of consistency in advertising policies regarding cannabis
                       3.2.3. Case Study Analysis
                   3.3. Business Environment Analysis
                       3.3.1. Industry Analysis - Porter’s
                           3.3.1.1. Supplier power
                           3.3.1.2. Buyer power
                           3.3.1.3. Substitution threat
                           3.3.1.4. Threat of new entrant
                           3.3.1.5. Competitive rivalry
                       3.3.2. PESTLE Analysis
                   3.4. Regulatory Landscape
Chapter 4. U.S. Cannabis Market Segment Analysis, By Source, 2018 - 2030 (USD Million)
                   4.1. Definition and Scope
                   4.2. Source Segment Dashboard
                   4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                   4.4. Hemp
                       4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       4.4.2. Hemp oil
                           4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       4.4.3. Industrial Hemp
                           4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                   4.5. Marijuana
                           4.5.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       4.5.2. Flower
                           4.5.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       4.5.3. Oil and Tinctures
                           4.5.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. U.S. Cannabis Market Segment Analysis, By Derivative, 2018 - 2030 (USD Million)
                   5.1. Definition and Scope
                   5.2. Derivatives Segment Dashboard
                   5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                   5.4. CBD
                       5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                   5.5. THC
                       5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                   5.6. Others
                       5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. U.S. Cannabis Market Segment Analysis, By End-use, 2018 - 2030 (USD Million)
                   6.1. Definition and Scope
                   6.2. End-use Segment Dashboard
                   6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                   6.4. Industrial Use
                       6.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                   6.5. Medical Use
                       6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.2. Chronic Pain
                           6.5.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.3. Depression and Anxiety
                           6.5.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.4. Arthritis
                           6.5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.5. Post Traumatic Stress Disorder (PTSD)
                           6.5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.6. Cancer
                           6.5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.7. Migraines
                           6.5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.8. Epilepsy
                           6.5.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.9. Alzheimer’s Disease
                           6.5.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.10. Multiple Sclerosis
                           6.5.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.11. Amyotrophic Lateral Sclerosis
                           6.5.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.12. Tourette’s Syndrome
                           6.5.12.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.13. Diabetes
                           6.5.13.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.14. Parkinson's Disease
                           6.5.14.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.15. Glaucoma
                           6.5.15.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                       6.5.16. Others
                           6.5.16.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
                   6.6. Recreational Use
                       6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
                   7.1. Recent Developments & Impact Analysis, by Key Market Participants
                   7.2. Company Categorization
                   7.3. Company Market Position Analysis
                   7.4. Company Profiles
                       7.4.1. Tilray Brands
                           7.4.1.1. Overview
                           7.4.1.2. Financial Performance
                           7.4.1.3. Service Benchmarking
                           7.4.1.4. Strategic Initiatives
                       7.4.2. Canopy Growth Corporation
                           7.4.2.1. Overview
                           7.4.2.2. Financial Performance
                           7.4.2.3. Service Benchmarking
                           7.4.2.4. Strategic Initiatives
                       7.4.3. Medical Marijuana, Inc.
                           7.4.3.1. Overview
                           7.4.3.2. Financial Performance
                           7.4.3.3. Service Benchmarking
                           7.4.3.4. Strategic Initiatives
                       7.4.4. NuLeaf Naturals, LLC
                           7.4.4.1. Overview
                           7.4.4.2. Financial Performance
                           7.4.4.3. Service Benchmarking
                           7.4.4.4. Strategic Initiatives
                       7.4.5. CV Sciences, Inc.
                           7.4.5.1. Overview
                           7.4.5.2. Financial Performance
                           7.4.5.3. Service Benchmarking
                           7.4.5.4. Strategic Initiatives
                       7.4.6. CHARLOTTE’S WEB.
                           7.4.6.1. Overview
                           7.4.6.2. Financial Performance
                           7.4.6.3. Service Benchmarking
                           7.4.6.4. Strategic Initiatives
                       7.4.7. The Cronos Group
                           7.4.7.1. Overview
                           7.4.7.2. Financial Performance
                           7.4.7.3. Service Benchmarking
                           7.4.7.4. Strategic Initiatives
                       7.4.8. Organigram Holding, Inc
                           7.4.8.1. Overview
                           7.4.8.2. Financial Performance
                           7.4.8.3. Service Benchmarking
                           7.4.8.4. Strategic Initiatives
                       7.4.9. Irwin Naturals
                           7.4.9.1. Overview
                           7.4.9.2. Financial Performance
                           7.4.9.3. Service Benchmarking
                           7.4.9.4. Strategic Initiatives
                       7.4.10. Aurora Cannabis
                           7.4.10.1. Overview
                           7.4.10.2. Financial Performance
                           7.4.10.3. Service Benchmarking
                           7.4.10.4. Strategic Initiatives


List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. cannabis market, by source, 2018 - 2030 (USD Million)
Table 4 U.S. cannabis market, by derivatives, 2018 - 2030 (USD Million)
Table 5 U.S. cannabis market, by end-use, 2018 - 2030 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Value-chain-based sizing & forecasting
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market research approaches
Fig. 7 Market formulation & validation
Fig. 8 U.S. cannabis market: market outlook
Fig. 9 U.S. cannabis competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook.
Fig. 12 Industry value chain analysis
Fig. 13 U.S. cannabis market driver impact
Fig. 14 U.S. cannabis market restraint impact
Fig. 15 U.S. cannabis market strategic initiatives analysis
Fig. 16 U.S. cannabis market: Source movement analysis
Fig. 17 U.S. cannabis market: Source outlook and key takeaways
Fig. 18 Hemp market estimates and forecasts, 2018 - 2030
Fig. 19 Hemp Oil market estimates and forecasts, 2018 - 2030
Fig. 20 Industrial Hemp market estimates and forecasts, 2018 - 2030
Fig. 21 Marijuana market estimates and forecasts, 2018 - 2030
Fig. 22 Flower market estimates and forecasts, 2018 - 2030
Fig. 23 Oil and Tinctures market estimates and forecasts, 2018 - 2030
Fig. 24 U.S. cannabis market: Derivatives movement analysis
Fig. 25 U.S. cannabis market: Derivatives outlook and key takeaways
Fig. 26 CBD market estimates and forecasts, 2018 - 2030
Fig. 27 THC market estimates and forecasts, 2018 - 2030
Fig. 28 Others market estimates and forecasts, 2018 - 2030
Fig. 29 U.S. cannabis market: End-use movement analysis
Fig. 30 U.S. cannabis market: End-use outlook and key takeaways
Fig. 31 Industrial Use market estimates and forecasts, 2018 - 2030
Fig. 32 Medical Use market estimates and forecasts, 2018 - 2030
Fig. 33 Chronic Pain market estimates and forecasts, 2018 - 2030
Fig. 34 Depression and Anxiety market estimates and forecasts, 2018 - 2030
Fig. 35 Arthritis market estimates and forecasts, 2018 - 2030
Fig. 36 Post Traumatic Stress Disorder (PTSD) market estimates and forecasts, 2018 - 2030
Fig. 37 Cancer market estimates and forecasts, 2018 - 2030
Fig. 38 Migraines market estimates and forecasts, 2018 - 2030
Fig. 39 Epilepsy market estimates and forecasts, 2018 - 2030
Fig. 40 Alzheimer’s market estimates and forecasts, 2018 - 2030
Fig. 41 Multiple Sclerosis market estimates and forecasts, 2018 - 2030
Fig. 42 AIDS market estimates and forecasts, 2018 - 2030
Fig. 43 Amyotrophic Lateral Sclerosis market estimates and forecasts, 2018 - 2030
Fig. 44 Tourette’s market estimates and forecasts, 2018 - 2030
Fig. 45 Diabetes market estimates and forecasts, 2018 - 2030
Fig. 46 Parkinson's market estimates and forecasts, 2018 - 2030
Fig. 47 Glaucoma market estimates and forecasts, 2018 - 2030
Fig. 48 Others market estimates and forecasts, 2018 - 2030
Fig. 49 Recreational Use market estimates and forecasts, 2018 - 2030
Fig. 50 Key company categorization

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon